Year All2026202520242023202220212020201920182017201620152014 ABIVAX receives French regulatory Approval to Begin Clinical Trial of ABX464 in Ulcerative Colitis September 20, 2017 Read More FIRST PATIENT DOSED IN THREE-MONTH COHORT OF PHASE 2A STUDY OF ORAL ABX464 IN HIV-SUPPRESSED PATIENTS September 18, 2017 Read More ABIVAX and Evotec enter into Strategic Collaboration to Develop Novel Antiviral Agents September 07, 2017 Read More ABIVAX to present latest clinical data on ABX464 at the International Aids Society Conference in Paris, France July 13, 2017 Read More New Experimental Data on Anti-inflammatory Effects of ABX464, ABIVAX’s First-in-Class Drug Candidate to Achieve Functional Cure in HIV-Patients, Published in Nature Scientific Reports July 12, 2017 Read More Prof. Jamal Tazi, inventor of ABX464, ABIVAX’s lead drug candidate for inducing a functional cure for HIV, awarded the CNRS Medal of Innovation 2017 June 15, 2017 Read More ABIVAX to receive €390,000 from Bpifrance for the development of its Ebola hyperimmune candidate June 12, 2017 Read More ABIVAX announces the publication of its 2016 Registration Document and highlights the development stage of its portfolio May 11, 2017 Read More ABIVAX confirms trading resumption May 02, 2017 Read More First ever evidence of treatment-induced reduction in HIV reservoirs May 02, 2017 Read More
ABIVAX receives French regulatory Approval to Begin Clinical Trial of ABX464 in Ulcerative Colitis September 20, 2017 Read More
FIRST PATIENT DOSED IN THREE-MONTH COHORT OF PHASE 2A STUDY OF ORAL ABX464 IN HIV-SUPPRESSED PATIENTS September 18, 2017 Read More
ABIVAX and Evotec enter into Strategic Collaboration to Develop Novel Antiviral Agents September 07, 2017 Read More
ABIVAX to present latest clinical data on ABX464 at the International Aids Society Conference in Paris, France July 13, 2017 Read More
New Experimental Data on Anti-inflammatory Effects of ABX464, ABIVAX’s First-in-Class Drug Candidate to Achieve Functional Cure in HIV-Patients, Published in Nature Scientific Reports July 12, 2017 Read More
Prof. Jamal Tazi, inventor of ABX464, ABIVAX’s lead drug candidate for inducing a functional cure for HIV, awarded the CNRS Medal of Innovation 2017 June 15, 2017 Read More
ABIVAX to receive €390,000 from Bpifrance for the development of its Ebola hyperimmune candidate June 12, 2017 Read More
ABIVAX announces the publication of its 2016 Registration Document and highlights the development stage of its portfolio May 11, 2017 Read More
